article Open AccessTop 1% cited

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial

Journal of the American Academy of Dermatology · 2017 · Vol. 76(3) · pp. 418–431

Kristian Reich✉(Dermatologikum Hamburg)April W. Armstrong(University of Southern California)Peter Foley(St Vincent's Hospital)Michael Song(Janssen (United States))Yasmine Wasfi(Janssen (United States))B. Randazzo(Janssen (United States))Shu Li(Janssen (United States))Yaung‐Kaung Shen(Janssen (United States))Kenneth B. Gordon(Northwestern University)

View via DOI Publisher page

Abstract

Guselkumab is a highly effective, well-tolerated, maintenance therapy, including in adalimumab nonresponders.

Psoriasis: Treatment and Pathogenesis Dermatology and Skin Diseases Asthma and respiratory diseasesMedicinePsoriasis Area and Severity IndexAdalimumabPsoriasisPlaceboInternal medicineRandomized controlled trialDermatology Life Quality IndexSurgeryGastroenterology

MeSH terms

AdalimumabAdultAntibodies, MonoclonalDermatologic AgentsDouble-Blind MethodFemaleHumansMaleMiddle AgedPlacebosPsoriasisQuality of LifeSeverity of Illness IndexRetreatmentWithholding Treatment

Citations

718

FWCI

34.76

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial